Siltuximab for Multicentric Castleman Disease-Letter

Clin Cancer Res. 2015 Oct 15;21(20):4740. doi: 10.1158/1078-0432.CCR-15-1310.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Castleman Disease / drug therapy*
  • Drug Approval*
  • Humans
  • United States Food and Drug Administration*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents